GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (FRA:DUL) » Definitions » Cyclically Adjusted PB Ratio

Alnylam Pharmaceuticals (FRA:DUL) Cyclically Adjusted PB Ratio : 12.32 (As of May. 14, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-14), Alnylam Pharmaceuticals's current share price is €138.75. Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €11.26. Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 12.32.

The historical rank and industry rank for Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:DUL' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.66   Med: 12.86   Max: 25.16
Current: 12.62

During the past years, Alnylam Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 25.16. The lowest was 4.66. And the median was 12.86.

FRA:DUL's Cyclically Adjusted PB Ratio is ranked worse than
92.25% of 645 companies
in the Biotechnology industry
Industry Median: 1.79 vs FRA:DUL: 12.62

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alnylam Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €-1.595. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.26 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.02 11.59 13.79 18.66 15.53

Alnylam Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.73 15.04 14.11 15.53 12.59

Competitive Comparison of Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=138.75/11.26
=12.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Alnylam Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.595/129.4194*129.4194
=-1.595

Current CPI (Mar. 2024) = 129.4194.

Alnylam Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 9.086 100.560 11.694
201409 9.154 100.428 11.797
201412 9.835 99.070 12.848
201503 16.420 99.621 21.331
201506 14.847 100.684 19.084
201509 13.901 100.392 17.920
201512 13.644 99.792 17.695
201603 12.494 100.470 16.094
201606 11.425 101.688 14.541
201609 10.544 101.861 13.397
201612 10.151 101.863 12.897
201703 9.026 102.862 11.356
201706 10.899 103.349 13.648
201709 9.618 104.136 11.953
201712 14.976 104.011 18.634
201803 14.165 105.290 17.411
201806 13.796 106.317 16.794
201809 12.546 106.507 15.245
201812 11.311 105.998 13.810
201903 12.867 107.251 15.527
201906 13.996 108.070 16.761
201909 13.108 108.329 15.660
201912 11.542 108.420 13.778
202003 10.794 108.902 12.828
202006 10.748 108.767 12.789
202009 8.882 109.815 10.468
202012 7.175 109.897 8.450
202103 6.631 111.754 7.679
202106 5.972 114.631 6.742
202109 5.378 115.734 6.014
202112 4.331 117.630 4.765
202203 3.017 121.301 3.219
202206 1.376 125.017 1.424
202209 -0.555 125.227 -0.574
202212 -1.205 125.222 -1.245
202303 -1.949 127.348 -1.981
202306 -3.016 128.729 -3.032
202309 -1.239 129.860 -1.235
202312 -1.608 129.419 -1.608
202403 -1.595 129.419 -1.595

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alnylam Pharmaceuticals  (FRA:DUL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alnylam Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (FRA:DUL) Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (FRA:DUL) Headlines

No Headlines